Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

14 results about "Reabsorption" patented technology

In renal physiology, reabsorption or tubular reabsorption is the process by which the nephron removes water and solutes from the tubular fluid (pre-urine) and returns them to the circulating blood. It is called reabsorption (and not absorption) both because these substances have already been absorbed once (particularly in the intestines) and because the body is reclaiming them from a postglomerular fluid stream that is well on its way to becoming urine (that is, they will soon be lost to the urine unless they are reclaimed). Substances are reabsorbed from the tubule into the peritubular capillaries. This happens as a result of sodium transport from the lumen into the blood by the Na⁺/K⁺ATPase in the basolateral membrane of the epithelial cells. Thus, the glomerular filtrate becomes more concentrated, which is one of the steps in forming urine. Reabsorption allows many useful solutes (primarily glucose and amino acids), salts and water that have passed through Bowman's capsule, to return to the circulation. These solutes are reabsorbed isotonically, in that the osmotic potential of the fluid leaving the proximal convoluted tubule is the same as that of the initial glomerular filtrate. However, glucose, amino acids, inorganic phosphate, and some other solutes are reabsorbed via secondary active transport through cotransport channels driven by the sodium gradient.

Application of product of targeted Vasorin protein in preparation of product for diagnosing or treating kidney diseases with reduced glucose tolerance

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.
Owner:ZHU XIANYI MEMORIAL HOSPITAL OF TIANJIN MEDICAL UNIV (TIANJIN MEDICAL UNIV METABOLIC DISEASE HOSPITAL TIANJIN METABOLIC DISEASE PREVENTION CENT)

Traditional Chinese medicine composition for treating hyperuricemia and application thereof

The invention discloses a traditional Chinese medicine composition for treating hyperuricemia and application thereof, and belongs to the technical field of traditional Chinese medicines. The preparation method of the traditional Chinese medicine composition comprises the following steps: mixing ganoderma lucidum spore powder and idesia polycarpa fruit powder according to a mass part ratio of (10-90): (90-10), extracting by using a supercritical CO2 fluid extraction technology to obtain an extract phase, then carrying out decompression analysis to precipitate an extract, and drying to obtain traditional Chinese medicine composition powder. The invention provides the traditional Chinese medicine composition compounded by the ganoderma lucidum spore oil and the idesia oil, and cell experiments and animal experiments prove that the traditional Chinese medicine composition can remarkably inhibit uric acid synthesis and reabsorption, so that the level of serum uric acid is reduced, renal function impairment caused by hyperuricemia is improved, and the curative effect is improved. The compound can be used as a functional raw material for preparing a product for treating hyperuricemia or improving kidney injury caused by hyperuricemia; the raw materials are easy to obtain, the cost is low, the safety is high, and good development and application values are achieved.
Owner:ZHEJIANG FORESTRY UNIVERSITY

Kidney organoid culture and multifunctional detection integrated micro-fluidic chip

The invention discloses a kidney organoid culture and multifunctional detection integrated micro-fluidic chip, which is characterized in that a first chip (top layer) is provided with six independent cell culture chambers, the bottom is provided with a porous membrane, glomerular cells differentiated by human induced pluripotent stem cells are inoculated, and a blood filtration function is simulated; the second chip (middle layer) is provided with a raw urine-like collecting chamber, and a porous membrane is used for receiving the filtrate and detecting final urine-like components; and the third chip (bottom layer) is inoculated with vascular endothelial cells to simulate renal tubule reabsorption and blood purification processes. According to the invention, glomerular filtration and renal tubule reabsorption full-function chains are coupled, and the limitation of single function simulation is broken through; the parallel culture room supports synchronous drug toxicity testing or disease modeling; a multi-valve dynamic control system can accurately simulate pathological microenvironments such as high glucose and renal toxicity; and in-situ multi-parameter real-time analysis is realized through three paths of detection outlets. The chip provides a highly bionic in-vitro platform for drug screening, diabetic nephropathy mechanism research and kidney injury model construction.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Use of an article targeting vasorin protein in the manufacture of a product for the diagnosis or treatment of impaired glucose tolerance nephropathy

The application provides application of a preparation targeting a Vasorin protein in preparation of a diagnosis or treatment product for impaired glucose tolerance kidney disease, and belongs to the technical field of biological medicine. Vasorin is used as a biomarker for impaired glucose tolerance kidney disease, and absolute quantification of the level of Vasorin in urine of patients through ELISA technology has great clinical value and practical significance for early discovery and intervention of impaired glucose tolerance kidney disease. Taking a gene controlling expression of Vasorin or the Vasorin protein as a target, overexpression of the gene or the protein by using a specific carrier can effectively improve lipid droplet deposition in renal tubular epithelial cells, excessive generation of reactive oxygen species (ROS), and the ability of the renal tubular epithelial cells to reabsorb albumin, so that effective treatment of impaired glucose tolerance kidney disease is achieved.
Owner:ZHU XIANYI MEMORIAL HOSPITAL OF TIANJIN MEDICAL UNIV (TIANJIN MEDICAL UNIV METABOLIC DISEASE HOSPITAL TIANJIN METABOLIC DISEASE PREVENTION CENT)

Lactobacillus fermentum HF17 capable of inhibiting xanthine oxidase activity and application of lactobacillus fermentum HF17

The invention discloses lactobacillus fermentum HF17 capable of inhibiting xanthine oxidase activity and application of the lactobacillus fermentum HF17. The lactobacillus fermentum HF17 is lactobacillus fermentum and is preserved in the China Center for Type Culture Collection (CCTCC), and the lactobacillus fermentum HF17 is preserved in the China Center for Type Culture Collection (CCTCC). The preservation number of the strain is CCTCC (China Center For Type Culture Collection) Animal experiments show that the strain has the function of inhibiting the activity of xanthine oxidase to reduce uric acid, and lactobacillus fermentum HF17 reduces gene expression of purine metabolism related enzymes in the liver through mediation to inhibit synthesis of uric acid; according to the present invention, the gene expression of the uric acid secretion transporter in the kidney is up-regulated, the gene expression of the uric acid resorption transporter is down-regulated, and the excretion of uric acid in the mouse body is promoted so as to improve the uric acid level of the hyperuricemia mouse, improve the species richness and diversity of the intestinal flora, and improve the hyperuricemia-related metabolic disorder and other phenomena;
Owner:HARBIN INST OF TECH

Method for assisting evaluation of condition of kidneys, system for evaluating condition of kidneys, and program for evaluating condition of kidneys

The present invention provides a method for assisting in the evaluation of the condition of kidneys, a system for evaluating the condition of kidneys, and a program for evaluating the condition of kidneys, using, as an index, the ratio of reabsorption of D-serine and / or D-asparagine in target kidneys and excretion of the D-serine and / or D-asparagine. The present invention also provides a method for monitoring the condition of kidneys and a method for monitoring the effect of treatment on kidney disease.
Owner:KAGAMI INC +1

Lactococcus lactis SWU-HX39 for relieving hyperuricemia

The present application discloses a lactic acid pediococcus SWU-HX39 with the function of reducing uric acid, and the classification name is lactic acid pediococcus (Pediococcus acidilactici) Pediococcus acidilactici ), which is preserved in the China General Microbiological Culture Collection Center, with the preservation number of CGMCC No.33055, the preservation date of December 13, 2024, and the preservation address of No.3, Xili, Beichen West Road, Chaoyang District, Beijing. The lactic acid pediococcus SWU-HX39 can relieve the kidney damage caused by high uric acid, reduce the synthesis of uric acid, lower the concentration of uric acid in blood, improve the excretion of uric acid in the body, reduce the reabsorption of uric acid in the body, and achieve the effect of reducing uric acid. In addition, SWU-HX39 can reduce the expression of LPS and the expression of inflammatory factors IL-1beta, IL-6 and TNF alpha. That is, it has the functions of anti-inflammation and relieving liver inflammation, and can also increase the content of SCFAs in the body of patients with high uric acid, especially propionic acid, so as to reduce the uric acid level and improve the abnormal uric acid content.
Owner:SOUTHWEST UNIV

Preparation method and application of rhizoma polygonati total flavonoids

The invention belongs to the technical field of extraction and separation, and particularly relates to a preparation method and application of rhizoma polygonati total flavonoids. According to the preparation method provided by the invention, the extraction rate of the total flavonoids of the rhizoma polygonati can be increased, 324 flavonoid components are analyzed and identified in the extracted flavonoid extract and mainly contain flavones, flavanone, flavonol, isoflavone and other flavonoids, the content of effective components is high, the preparation process is simple and controllable, and the method is suitable for large-scale production; the total flavonoids of polygonatum sibiricum provided by the invention can effectively relieve oxidative stress of HK-2 cells induced by uric acid and improve the oxidation resistance of the cells, so that the toxic effect of a hyperuricemia environment on kidney cells is relieved; and further research shows that by adjusting the expression of a kidney uric acid transporter URAT1, uric acid reabsorption can be reduced, kidney uric acid excretion can be promoted, and the compound has a good application prospect in preparation of uric acid lowering drugs, anti-hyperuricemia drugs and the like.
Owner:SHANDONG ACADEMY OF AGRICULTURAL SCIENCES +1

Gallus gallus domesticus beta-lactoglobulin reabsorption-mediated gambogic acid renal delivery system, synthetic method and application thereof

This invention belongs to the field of biomedicine and nanomedicine delivery technology, and relates to a precise renal-targeted delivery system for gambogeylic acid mediated by the β-lactoglobulin reabsorption mechanism, its synthesis method, and applications. The system comprises β-lactoglobulin-PEG-gambogeylic acid nanoparticles, containing β-lactoglobulin as a targeting carrier and gambogeylic acid as the active ingredient, covalently linked by a polyethylene glycol chain. This invention utilizes the suitable molecular size of β-lactoglobulin and its ability to be recognized and reabsorbed by the megalin / cubilin receptor system of renal tubular epithelial cells to construct a nanodelivery system that mimics the physiological process of endogenous protein "filtration-reabsorption." Experiments have shown that this system significantly improves the water solubility and biocompatibility of gambogeylic acid, enabling selective accumulation in the kidneys and efficient capture by renal tubular epithelial cells in vivo. It exhibits superior therapeutic effects in a mouse model of cisplatin- and glycerol-induced acute kidney injury, significantly outperforming the positive control drug NAC.
Owner:JIANGSU UNIV OF SCI & TECH

Composition for prevention, amelioration, or treatment of urination-related diseases comprising cephalotocin

ActiveUS12558397B2Peptide/protein ingredientsUrinary disorderDiseaseVasopressin receptor
The present invention relates to a composition for the prevention, amelioration, or treatment of urination-related disases, comprising cephalotocin. The cephalotocin according to the present invention modulates oxytocin receptors and vasopressin receptors, and has the effect of reducing urine volume by promoting water reabsorption in the kidneys. This means that cephalotocin has a significant antidiuretic effect, and thus, the cephalotocin of the present invention can be variously used in the field of prevention, amelioration, or treatment of urinary disorders or urination-related diseases.
Owner:KOREA RES INST OF CHEM TECH +1

Application of cinchona element Ia as uric acid reducing medicine

The invention discloses an application of cinchona element Ia as a uric acid lowering drug, and finds that the cinchona element Ia has a remarkable inhibition effect on expression of GLUT9 protein for the first time, and reabsorption of the kidney to uric acid can be effectively reduced by inhibiting expression of the GLUT9 protein, so that excretion of the uric acid from urine is promoted, the serum uric acid level is reduced, and the toxic and side effects of the kidney are reduced. And a new effective way is provided for treatment of hyperuricemia and gout.
Owner:GUIZHOU PROVINCIAL PEOPLES HOSPITAL

Compositions and methods for treating metabolic disease

The invention described herein relates to oral dosage form therapies for treating metabolic disorders using combinations of inhibitors of SGLT1 and SGLT2. In such dosage forms, SGLT1 is effective in the intestinal lumen, and is either not absorbed, or poorly absorbed, while the SGLT2 inhibitor inhibits sugar reabsorption in the kidney by inhibiting SGLT2 activity. Metabolic disorders treated by combined SGLT1 and SGLT2 oral dosage forms include disorders associated with abnormal accumulation of liver lipids, which may also be copresent with hyperglycemia. Combinations of SGLT1 and SGLT2 inhibitors are contemplated herein, particularly combinations.
Owner:VOGENX

Application of < 18 > F-lactitol in preparation of diabetic nephropathy detection product

PendingCN120992955ADisease diagnosisBiological testingDiabetic kidneyGlucose uptake
The invention discloses application of < 18 > F-lactitol in preparation of a diabetic nephropathy detection product, and belongs to the technical field of biomedical detection. In order to solve the problem that the action and mechanism of STRs in the kidney through SGLT2-dependent glucose reabsorption and transport are not clear yet, 18F-labeled lactitol is used, the in-vivo glucose level, kidney pathology and SGLT2 expression are detected through PET / CT, and the glucose uptake rate is labeled through in-vitro fluorescence, so that the effect and mechanism of STRs in the kidney through SGLT2-dependent glucose reabsorption and transport are determined. The method is used for evaluating the glucose reabsorption effect and mechanism of the STRs in STZ (streptozotocin)-induced diabetic mice and HK-2 cells. The result shows that the 18F-lactitol can be sensitively and specifically combined with the STRs, the biological distribution of the 18F-lactitol and the expression of the STRs in the kidney of a diabetic mouse are obviously reduced, the expression of the SGLT2 is up-regulated, and the lactitol or siRNA-STRs can obviously reduce the influence of high glucose on the expression of the STRs and the SGLT2 and glucose absorption. Therefore, the STRs can be used as a new therapeutic target for diabetes, and the < 18 > F-lactitol labeled PET / CT can become a novel probe for detecting diabetic kidney injury.
Owner:THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV